Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Dyadic International (NASDAQ:DYAI) Financial Review

Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) and Dyadic International (NASDAQ:DYAI – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Earnings and Valuation

This table compares Kiniksa Pharmaceuticals International and Dyadic International”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kiniksa Pharmaceuticals International $945.96 million 7.93 $59.01 million $1.30 73.42
Dyadic International $3.09 million 4.23 -$7.36 million ($0.21) -1.55

Kiniksa Pharmaceuticals International has higher revenue and earnings than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Kiniksa Pharmaceuticals International has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.

Insider & Institutional Ownership

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 27.9% of Dyadic International shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 20.9% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Kiniksa Pharmaceuticals International and Dyadic International, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kiniksa Pharmaceuticals International 0 2 8 0 2.80
Dyadic International 1 0 0 0 1.00

Kiniksa Pharmaceuticals International presently has a consensus target price of $102.38, indicating a potential upside of 7.27%. Given Kiniksa Pharmaceuticals International’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Kiniksa Pharmaceuticals International is more favorable than Dyadic International.

Profitability

This table compares Kiniksa Pharmaceuticals International and Dyadic International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kiniksa Pharmaceuticals International 11.58% 17.27% 12.64%
Dyadic International -226.85% -2,920.31% -93.70%

Summary

Kiniksa Pharmaceuticals International beats Dyadic International on 13 of the 14 factors compared between the two stocks.

About Kiniksa Pharmaceuticals International

(Get Free Report)

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.

About Dyadic International

(Get Free Report)

Dyadic International is a biotechnology company developing microbial expression systems to produce proteins for human and animal health applications. Its platforms are designed to help partners develop and manufacture biologics, including vaccines, therapeutics and diagnostic products. The company’s technologies include its C1 fungal expression system, based on a non-pathogenic microorganism, and its Dapibus yeast platform. Dyadic licenses these systems and related expertise to collaborators and also pursues development of selected products for health applications.

Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.